MOLN Stock - Molecular Partners AG
Unlock GoAI Insights for MOLN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.97M | $7.04M | $189.56M | $9.33M | $9.34M |
| Gross Profit | $-42,534,000 | $-40,806,000 | $138.81M | $-46,388,000 | $-46,731,000 |
| Gross Margin | -855.8% | -579.8% | 73.2% | -497.2% | -500.1% |
| Operating Income | $-61,217,000 | $-61,108,000 | $116.61M | $-63,418,000 | $-58,326,000 |
| Net Income | $-54,043,000 | $-61,984,000 | $117.85M | $-63,785,000 | $-62,764,000 |
| Net Margin | -1087.4% | -880.7% | 62.2% | -683.7% | -671.7% |
| EPS | $-1.59 | $-1.89 | $3.63 | $-2.06 | $-2.51 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 30th 2022 | RBC Capital Mkts | Downgrade | Sector Perform | - |
| August 29th 2022 | SVB Leerink | Downgrade | Market Perform | $8← $30 |
| May 25th 2022 | Credit Suisse | Upgrade | Neutral | - |
| April 27th 2022 | Credit Suisse | Downgrade | Underperform | - |
Earnings History & Surprises
MOLNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | $-0.35 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q3 2025 | Aug 25, 2025 | $-0.53 | $-0.67 | -26.4% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.42 | $-0.50 | -18.6% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.44 | $-0.34 | +22.7% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.63 | $-0.57 | +9.5% | ✓ BEAT |
Q3 2024 | Aug 26, 2024 | $-1.26 | $-0.51 | +59.5% | ✓ BEAT |
Q2 2024 | May 16, 2024 | — | $-0.39 | — | — |
Q1 2024 | Mar 14, 2024 | $-0.97 | $-0.68 | +29.9% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | — | $-0.40 | — | — |
Q3 2023 | Aug 23, 2023 | — | $-0.55 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.49 | — | — |
Q1 2023 | Mar 9, 2023 | $0.90 | $-0.56 | -162.2% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $-0.66 | $-0.42 | +36.0% | ✓ BEAT |
Q3 2022 | Aug 25, 2022 | $-0.66 | $-0.15 | +77.1% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.66 | $4.99 | +860.8% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-1.04 | $-0.56 | +46.2% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | — | $-0.41 | — | — |
Q3 2021 | Aug 26, 2021 | — | $-0.60 | — | — |
Q2 2021 | Jun 16, 2021 | — | $-0.60 | — | — |
Latest News
JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $3.75
➖ NeutralReported Sunday, Molecular Partners Presents Updated MP0533 Phase 1/2a AML Data At ASH Annual Meeting With Clinical Benefit And Acceptable Safety Across Dosing Regimens
📈 PositiveMolecular Partners Unveils First Patient Images Of Half-life Engineered MP0712 Demonstrating Specific Uptake And Limited Healthy Organ Exposure In DLL3 Positive Tumors
📈 PositiveMolecular Partners shares are trading higher after the company announced it will present further preclinical proof-of-concept data on its logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation in a poster at the Society for Immunotherapy of Cancer 2025 meeting.
📈 PositiveMolecular Partners Demonstrates Tumor-Localized Immune Activation With Logic-Gated CD3 Switch-DARPin Inducing Significant Tumor Regression Without Systemic Cytokine Release
📈 PositiveMolecular Partners Q3 EPS $(1.65) Misses $(0.46) Estimate
📉 NegativeJP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4
➖ NeutralMolecular Partners shares are trading lower after the company reported a year-over-year decrease in Q2 EPS results.
📉 NegativeMolecular Partners Q2 EPS $(0.67) Down from $(0.56) YoY
📉 NegativeMolecular Partners To Reduce Workforce By Up To 24%
📉 NegativeFrequently Asked Questions about MOLN
What is MOLN's current stock price?
What is the analyst price target for MOLN?
What sector is Molecular Partners AG in?
What is MOLN's market cap?
Does MOLN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MOLN for comparison